In patients with type 2 diabetes mellitus (T2DM), the concurrent use of warfarin and sulphonylureas was associated with an increased risk of hypoglycaemia. There was no significant association between ...

In patients with type 2 diabetes (T2D), the concomitant use of sulphonylureas and beta-blockers was associated with an increased risk of severe hypoglycaemia compared with the use of sulphonylureas ...

There are several drugs that are being used for treatment of type 2 diabetes. Many type 2 diabetics suffer from kidney disorders that are caused by persistent high levels of blood sugar. The number of ...

New research shows that concomitant use of dipeptidyl peptidase 4 (DPP-4) inhibitors and sulphonylureas increases the risk of hypoglycaemia in patients with type 2 diabetes mellitus (T2DM). The ...

A study of nurses with diabetes in the US shows that long term use of sulphonylureas could increase the risk of coronary heart disease. Sulphonylureas are a widely prescribed class of drug for ...

Sulfonylureas are often added to metformin to improve glycemic control, but at the known risk of increasing hypoglycemia and weight gain. In a report published in the Lancet, more than 1,500 patients ...

Sulphonylureas, a type of drug widely used to treat type 2 diabetes, carries a greater risk of heart failure and death compared with metformin, another popular anti-diabetes drug. Sulphonylureas, a ...

Monotherapy for type two diabetes patients with most sulphonylureas has a higher risk of all-cause and cardiovascular death compared with metformin, say researchers. Compared to metformin, patients ...

GPs should consider alternatives to sulphonylureas in patients with Type 2 diabetes as their use is linked to an increase in cardiovascular disease, claim researchers. The US meta-analysis of 33 ...

Sulphonylureas, a type of drug widely used to treat type 2 diabetes, has a greater risk of causing heart failure and death as compared to metformin, another popular antidiabetes drug, according to a ...